How real-world data can tell the story of breast, ovarian and uterine cancers at a pivotal moment in women’s health
Nearly 4 million women worldwide are diagnosed with breast or gynecological cancers each year. Yet too many factors around these diseases are still poorly understood, including why there are so many disparities and variances in treatment and outcomes. Clinical trials have been helpful in illuminating some of these issues. And early approaches to leveraging real-world […]
Expanding insights into cancer with real-world data on solid tumors
Cancer comes in many forms, including hematologic malignancies that originate in blood-forming tissues or in the cells of the immune system, and solid tumors that form as abnormal masses of tissue and are named for the type of cells and classified by the organ or biologic structure from which they originate. Hematologic cancers, such as […]
Sustainability spotlight: How COTA is approaching corporate ecological responsibility
Since the turn of the century, there’s been a growing recognition that the health of our friends, families, & communities is intimately tied to the health of our physical environment. Safe water, clean air, & a diverse, balanced ecosystem are essential conditions for life to thrive & innovation to flourish.As a company focused on healthcare […]
Using AI to transform life sciences data analysis
Using AI to transform life sciences data analysis: An early look at CAILIN’s performance COTA has launched the COTA AI Language Insights Network (CAILIN) to expedite data analytics. CAILIN is an oncology trained, on-demand insight generator designed to answer a variety of fundamental questions pertaining to data analytics, including specific cohort size, subgroup breakdowns, […]
COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics
NEW YORK–(BUSINESS WIRE)–COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical researchers to access the combined resources of COTA’s research-grade electronic health record (EHR) data from academic and community care centers and Guardant’s clinicogenomic […]
Study Results from COTA, PreciseDx, and Baptist Health South Florida Confirm Novel AI Test, PreciseBreast is Equivalent to Oncotype DX at Predicting Breast Cancer Recurrence
Findings to be Presented at the San Antonio Breast Cancer Symposium NEW YORK, Dec. 9, 2024 /PRNewswire/ — COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an innovator in AI-powered digital pathology focused on oncology diagnostics, and Baptist Health South Florida today announced new study results validating the artificial intelligence […]
COTA and PHI, a subsidiary of Texas Oncology, partner to deliver precision medicine for cancer patients
For over a decade, COTA has been tackling the most complicated cancer data to produce real-world data that can power research that will improve care and expand treatment options for patients. And now, with the integration of AI into our data curation process, we have the potential to do data-assisted clinical research with more speed […]
COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™
COTA, PreciseDx and Baptist Health South Florida announced a collaboration to assess and validate the performance of the artificial intelligence (AI) -enabled PreciseBreast™ (PDxBr) test that predicts the likelihood of invasive breast cancer (IBC) recurrence.
Real-world data is helping to fine-tune care decisions for multiple myeloma patients: New research published at 2024 ASCO Annual Meeting
Researchers and clinicians agree that standards of care should be regularly reviewed and optimized based on the latest evidence to ensure that existing recommendations remain relevant.
Exploring standards of care in real-world settings with RWD
Real-world data (RWD) can help to illuminate patterns in therapy selection and the correlation to outcomes, giving oncologists and researchers some additional guidance on emerging trends in the oncology community.
